Natixis’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-100,000
Closed -$81.3M 1112
2025
Q1
$81.3M Buy
+100,000
New +$83.2M 0.44% 37

Other funds holding LLY

Natixis's LLY Position: Q1 2026 in Review

Natixis reduced its Eli Lilly (LLY) stake by 51% in Q1 2026, selling an estimated $105M and leaving 100,947 shares worth $92.8M. The position accounts for 0.33% of the portfolio, ranked #41.

Natixis first reported a position in LLY in Q2 2013 and has held it in 44 quarters since. The position peaked at $267M in Q1 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Natixis held 100,947 shares of Eli Lilly worth $92.8M as of Q1 2026.
  • Natixis sold 104,055 Eli Lilly shares in Q1 2026, an estimated $105M.
  • Eli Lilly made up 0.33% of Natixis's portfolio in Q1 2026, its #41 holding.
  • Natixis first reported a position in Eli Lilly in Q2 2013 and has held it in 44 quarters since.
  • Natixis's Eli Lilly position peaked at $267M in Q1 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.